To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
76
Pfizer Investigational Site
Pembury, Kent, United Kingdom
Pfizer Investigational Site
Royal Tunbridge Wells, Kent, United Kingdom
Pfizer Investigational Site
Ashton-under-Lyne, Lancs, United Kingdom
Primary endpoint is the time from randomization to delivery.
Individualised birth-weight ratio at delivery, Placental weight, Umbilical artery pulsatility index, Other indices of PET (incl. uric acid and maternal BP), Safety and toleration, Population PK, Fetal exposure (PK)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Bolton, United Kingdom
Pfizer Investigational Site
Dundee, United Kingdom
Pfizer Investigational Site
Fife, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
Manchester, United Kingdom
Pfizer Investigational Site
Manchester, United Kingdom